NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today...
Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused...
– First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m,...
– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on...
Barchart Research What to Expect from ARVN Earnings ARVN Generated May 6, 2026 Current Price $10.26 EPS Estimate $$-0.95 Consensus Rating Moderate Buy Average Move 7.19% Arvinas: Wall Street Bracing for...
NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced...
– VEPPANU ™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader – – Approval received in advance of FDA-assigned PDUFA date of June 5, 2026; Arvinas and...
– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy – – ARV-102 was well tolerated across all dose levels...
– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN, Conn., March 11, 2026...